FOR IMMEDIATE RELEASE January 3rd 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS   Throughout 2021 NCODA highlighted states throughout the country that took great strides to regulate Pharmacy […]

Written by: Jessie Signorelli PharmD, BCOP, Massachusetts General Hospital DOWNLAD HERE Description: This PQI will aim to review ponatinib efficacy and safety data as well as clinical pearls regarding supportive care and adverse event management.1 Background: Ponatinib (Iclusig®) is a third-generation tyrosine kinase inhibitor (TKI) with activity directed at BCR-ABL mutant kinase in patients with […]

Written by: Sara Moran Smith, PharmD, BCOP | M Health Fairview DOWNLOAD HERE Purpose: Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR)  inhibitors1 with 10-20% developing severe eruption.1 Studies have shown that the presence of this rash is indicative of response to treatment.1 Therefore, it is important to prevent […]

Written by: Dan Hertz, PharmD, PhD – University of Michigan College of Pharmacy DOWNLOAD HERE Description: The purpose of this PQI is to review recommendations for DPYD testing prior to initiation of treatment with fluoropyrimidine based chemotherapy and increase awareness of the clinical benefit of pre-treatment DPYD testing.  Background: Fluoropyrimidine (5-fluorouracil or capecitabine) chemotherapy is […]

Written By: Julia Stevens, PharmD, BCOP and Emmeline Academia, PharmD, BCOP – Beth Israel Deaconess Medical Center DOWNLOAD HERE Description: Fibroblast growth factor receptor (FGFR) inhibitors are a class of oral oncolytics approved for certain FGFR-altered malignancies, including bladder cancer (erdafitinib) and cholangiocarcinoma (infigratinib and pemigatinib). FGFR inhibitors come with unique adverse effect profiles and […]

Written By: Neal Dave, PharmD, and Natasha Khrystolubova, RPh, BCOP Download Here Description: Management of adverse effects related to regorafenib treatment in metastatic colorectal cancer. Optimal dosing and follow up are essential to help patients benefit fully while taking this medication. Background: Regorafenib is a multikinase inhibitor that has shown an overall survival benefit (6.4 […]

November 12, 2021   Statement From NCODA Legislative & Policy Advisory Committee Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org FOR IMMEDIATE RELEASE   Comment On Proposed LCD DL37810 Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms: Optimizing Management of Patients in Underserved and Minority Populations   CAZENOVIA, […]

Written by: Michelle Hoa and Natasha Heimbigner, PharmD – Summit Cancer Centers Download Here Description: Patients undergoing cancer treatment are more susceptible to infections due to their compromised immune system. This PQI will review which vaccinations cancer patients can or cannot use for the proper protection against preventable infections. Background: Cancer treatments weaken the immune […]

Written by: Danny Nguyen, MD, Nishan Tchekmedyian, MD, André K.D. Liem, MD, City of Hope National Medical Center DOWNLOAD HERE  Description: Mobocertinib (Exkivity™) is an oral EGFR tyrosine kinase inhibitor (TKI) designed to specifically target EGFR ex20ins mutations.1 This PQI will discuss effective strategies for side effect management. Background: Mobocertinib is indicated in locally advanced or […]

Written by: Megan Dillaman, PharmD, BCOP DOWNLOAD HERE Description: The purpose of this PQI is to discuss the use of belumosudil (Rezurock®) in the management of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation. Belumosudil was approved by the United States Food & Drug Administration (FDA) in 2021 with indication for use in patients […]

Written by: Julianna Darling, PharmD, Indiana University Health Simon Cancer Center Download Here Positive Quality Intervention: Fostamatinib (Tavalisse) use in Chronic Immune Thrombocytopenia Description: Fostamatinib is an oral spleen tyrosine kinase (Syk) inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a […]

Contact: Kevin Scorsone NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org Statement From NCODA Legislative & Policy Advisory Committee October 28, 2021 Patients Are The Priority: A Call For A Medically Integrated Community   CAZENOVIA, NY – New York State is the home of NCODA, and at one time locally owned pharmacies were commonplace. But […]